Payment overview · 2025
General Payments
$35,797.43
36 reported records · 9 companies
Healthcare provider profile · identity verified
Peter Rouvelas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BROOKLYN, NY · NPI 1245243609
Verified facts
What the public records show
CMS Open Payments records show Peter Rouvelas, M.D. received $35,797.43 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 99.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35,457.33 | 99.0% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.02 | 0.2% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $85.12 | 0.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.73 | 0.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.27 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.18 | 0.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.72 | 0.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.16 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.90 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,877.31 | 7 |
| Consulting Fee | $4,710.00 | 2 |
| Travel and Lodging | $2,053.25 | 5 |
| Food and Beverage | $1,156.87 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26,045.48 | 15 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $85.12 | 3 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $53.73 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 68 |
| Xarelto | Rivaroxaban | 176 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 45 |
| Metformin Hcl | Metformin Hcl | 159 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 38 |
| Carvedilol | Carvedilol | 157 | 34 |
| Furosemide | Furosemide | 154 | 32 |
| Ezetimibe | Ezetimibe | 138 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 112 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 26 |
| Jardiance | Empagliflozin | 109 | 21 |
| Entresto | Sacubitril/Valsartan | 98 | 18 |
| Eliquis | Apixaban | 88 | 16 |
| Vascepa | Icosapent Ethyl | 87 | 22 |
| Ozempic | Semaglutide | 81 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 19 |
| Potassium Chloride | Potassium Chloride | 71 | 12 |
| Glimepiride | Glimepiride | 64 | 13 |
| Farxiga | Dapagliflozin Propanediol | 60 | 16 |
| Lisinopril | Lisinopril | 60 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 57 | 14 |
| Benazepril Hcl | Benazepril Hcl | 54 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 15 |
| Candesartan Cilexetil | Candesartan Cilexetil | 51 | 14 |
| Labetalol Hcl | Labetalol Hcl | 50 | suppressed |
| Simvastatin | Simvastatin | 49 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Gabapentin | Gabapentin | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 30 |
| Famotidine | Famotidine | 33 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 32 | suppressed |
| Losartan Potassium | Losartan Potassium | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Niacin Er | Niacin | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35,797.43 · 36 records | Novo Nordisk Inc | AMVUTTRA, ELIQUIS, ENTRESTO, Korlym, LEQVIO, Ozempic, Repatha, Rybelsus, SAPIEN 3 Ultra RESILIA, VERQUVO, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error